Gilead - Stable Ischemic Heart Disease Flashcard

Stable Ischemic Heart Disease (SIHD) Flashcard

ACC/AHA Stable Ischemic Heart Disease GUIDELINES App brought to you free of charge courtesy of Gilead Sciences, Inc. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/582043

Contents of this Issue

Navigation

Page 1 of 1

F ASH card ™ Stable Ischemic Heart Disease Guideline-directed Medical Therapy for Relief of Symptoms Recommendation Class of Recommendation Level of Evidence Beta blockers should be prescribed as initial therapy for relief of symptoms in patients with SIHD CLASS I Benefit >>>Risk Procedure/Treatment SHOULD be performed/administered LEVEL B Limited populations evaluated Data derived from a single randomized trial or nonrandomized studies Calcium channel blockers or long-acting nitrates should be prescribed for relief of symptoms when beta blockers are contraindicated or cause unacceptable side efficts in patients with SIHD CLASS I LEVEL B Calcium channel blockers or long-acting nitrates, in combination with beta blockers, should be prescribed for relief of symptoms when initial treatment with beta blockers is unsuccessful in patients with SIHD CLASS I LEVEL B Sublingual nitroglycerin or nitroglycerin spray is recommended for immediate relief of angina in patients with SIHD CLASS I LEVEL B Ranolazine in combination with beta blockers can be useful when prescribed for relief of symptoms when initial treatment with beta blockers is not successful in patients with SIHD CLASS IIa Benefit >>Risk Additional studies with focused objectives needed IT IS REASONABLE to perform procedure/administer treatment LEVEL A Multiple populations evaluated Data derived from multiple randomized clinical trials or meta-analyses Ranolazine can be useful when prescribed as a substitute for beta blockers for relief of symptoms in patients with SIHD if initial treatment with beta blockers leads to unacceptable side effects or is ineffective or if initial treatment with beta blockers is contraindicated CLASS IIa LEVEL B Treatment with a long-acting nondihydropyridine calcium channel blocker (verpamil or diltiazem) instead of a beta blocker as initial therapy for relief of symptoms is reasonable in patients with SIHD CLASS IIa LEVEL B Adapted from 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. JACC 2012;60(24):1-121. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. Circulation 2012;126:e354-e471. Disclaimer is FLASHcard™ attempts to define principles of practice that should produce high-quality patient care. It focuses on the needs of primary care practice but also is applicable to providers at all levels. is FLASHcard™ should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. SIHDFC0113-2g TEL: 407.878.7606 • FAX: 407.878.7611 Copyright © 2015 All rights reserved GuidelineCentral.com

Articles in this issue

Links on this page

view archives of Gilead - Stable Ischemic Heart Disease Flashcard - Stable Ischemic Heart Disease (SIHD) Flashcard